Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EBShield Study
2023-508818-42-00Phase 3Authorised
- Sponsor
- TWi Biotechnology, Inc.
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in epidermolysis bullosa simplex (EBS) comparing Diacerein 1% ointment (AC-203) with Vehicle ointment (placebo) (2 arms). Primary endpoint: Investigator Global Assessment (IGA) treatment success in Treatment Area at Week 8. Planned start Apr 2024; status: authorised.
02
Drugs
AC-203
03
Conditions
epidermolysis bullosa simplex (EBS)
Beyond the preview
Go deeper on 2023-508818-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508818-42-00.